Shanxi and Chinese bio-joint research and development center for vaccines.

Pharmaceutical Network, June 30, the evening of June 28, Shanxi Provincial People's Government and China Biotechnology Co., Ltd(hereinafter referred to as "China Biology") signed a framework agreement to jointly build a vaccine research and development center and a vaccine clinical research base.Wu Wei, vice governor of Shanxi Province, said that in the past five years, Shanxi has conducted more than 10 phase III/IV clinical trials of vaccines in cooperation with Chinese organismsThe joint research and development center and vaccine clinical research base of the two sides are of great significance to promote the research and development and production capacity of vaccines and special effects drugs in Shanxi.In recent years, Chinese Biology has carried out three vaccine clinical projects at the Center for Disease Control and Prevention in Shanxi ProvinceAmong them, the tetravalent influenza vaccine has been technical review by the drug supervision department and clinical and production site verification, the tetravalent brain polysaccharide vaccine has been declared for production, and the tetravalent cervical cancer vaccine has been completed full immunization.Shanxi Province CDC is one of The earliest institutions in China to carry out clinical trials of vaccines, Chinese organisms in vaccine research and development, production, circulation and other aspects of the domestic leading, this cooperation, will be in human vaccines and other products inoculation, use, clinical effect evaluation, epidemiological investigation,adverse reactions
monitoring, prevention and control of new outbreaks of infectious diseases and other aspects of their respective advantages and common development.China's biological business scope covers human vaccines, blood products, medical beauty, animalhealth care, antibody drugs, medical diagnosis of six major biological productsHuman vaccines can produce 50 kinds of vaccines per year, with an annual output of more than 700 million doses, providing more than 80% of the national immunization programme vaccine;" We will further strengthen exchanges and cooperation and promote comprehensive cooperation between the two sides in various fieldsYang Xiaoming, chairman of China Biology, said that through the construction of a clinical research base for vaccines and a joint research center for vaccines, China Biology will continue to invest more in Shanxi through the development of new vaccine research and development and the transformation of scientific and technological achievements.Chinese organisms are responsible for the production and supply of more than 90% of Shanxi's immunization program vaccines, providing shanxi with more than 200 million doses of various vaccines"China Bio intends to restructure its acquisition of Shanxi Kangbao Bioproducts Co., Ltdand make additional investments to expand its blood production capacity." Yang Xiaoming said the total investment is expected to exceed 1 billion yuan.Wu Wei said that Shanxi has been ready to carry out all-round, multi-disciplinary and deep-level exchanges and cooperation under the framework agreement between the two sides, and will support policy support, supporting investment,talentsguarantee, etc., to ensure that many cooperation projects, including free 23-price pneumonia vaccine for the over-60s and emergency vaccination for the new crown pneumonia vaccine, will be implemented(Complete).